HOME PAGE

SeniorHealthWeek
Alzheimer's
Arthritis
Bladder Control
Breast Cancer
Cholesterol
Colorectal Cancer
Depression
Diabetes
Eye Disease
Acid Reflux - Ulcers
Heart Disease
Hypertension
Joint Replacement
Lung Cancer
Menopause
Osteoporosis
Parkinsons
Prostate Cancer
Skin Cancer

 

Senior Health Week: Arthritis
Health News You Can Use •

Arthritis News:

Public Citizen Urges FDA to Take Arthritis Drug Arava Off the Market

The advocacy group Public Citizen, citing toxicity concerns, has called on the U.S. Food and Drug Admistration to take the arthritis drug, Arava, off the market.

Public Citizen claimed the toxicity of Arava (leflunomide) is "clearly greater than that of methotrexate" – the gold standard in treatment of rheumatoid arthritis -- and said it has been linked to 130 severe liver reactions, 56 hospitalizations and 22 deaths.

The petition stated that although there were 5.5 times more prescriptions filled for methotrexate, there were "six times more reports of fatal liver damage" with leflunomide.

The petition added that, of the 12 cases of fatal liver damage,
leflunomide-induced liver toxicity "appears to be the most plausible
explanation," the group said.

"With a variety of better drug treatments available, there is no reason to subject patients to an accumulating list of added risks. [Arava] should be promptly removed from the market," the group said.

Source: Arthritis Week of March 31, 2002

 

 

 

About This Site
Privacy Policy
Advertising Policy
Contact Us

USE OF THIS SITE SIGNIFIES ACCEPTANCE OF THIS USER AGREEMENT: The information provided in this and our other sites is for educational purposes only, and it is not intended nor implied to be a substitute for professional medical advice. Always consult your own physician or healthcare provider with any questions you may have regarding a medical condition. Hypertext links to other sites are for the convenience of our Web site viewers and do not constitute any endorsement. We are not responsible for the content of linked sites in any way. This site is intended for personal use only and may not be used for any commercial purpose.